Literature DB >> 28903036

Culturing CTLs under Hypoxic Conditions Enhances Their Cytolysis and Improves Their Anti-tumor Function.

Yael Gropper1, Tali Feferman1, Tali Shalit2, Tomer-Meir Salame3, Ziv Porat3, Guy Shakhar4.   

Abstract

Cytotoxic T lymphocytes (CTLs) used in immunotherapy are typically cultured under atmospheric O2 pressure but encounter hypoxic conditions inside tumors. Activating CTLs under hypoxic conditions has been shown to improve their cytotoxicity in vitro, but the mechanism employed and the implications for immunotherapy remain unknown. We activated and cultured OT-I CD8 T cells at either 1% or 20% O2. Hypoxic CTLs survived, as well as normoxic ones, in vitro but killed OVA-expressing B16 melanoma cells more efficiently. Hypoxic CTLs contained similar numbers of cytolytic granules and released them as efficiently but packaged more granzyme-B in each granule without producing more perforin. We imaged CTL distribution and motility inside B16-OVA tumors using confocal and intravital 2-photon microscopy and observed no obvious differences. However, mice treated with hypoxic CTLs exhibited better tumor regression and survived longer. Thus, hypoxic CTLs may perform better in tumor immunotherapy because of higher intrinsic cytotoxicity rather than improved migration inside tumors.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cell migration; cytotoxic T cells; cytotoxicity; granzyme-B; hypoxia; imaging; immunometabolism; immunotherapy; melanoma; perforin

Mesh:

Substances:

Year:  2017        PMID: 28903036     DOI: 10.1016/j.celrep.2017.08.071

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  40 in total

Review 1.  Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.

Authors:  Jackie E Bader; Kelsey Voss; Jeffrey C Rathmell
Journal:  Mol Cell       Date:  2020-06-18       Impact factor: 17.970

Review 2.  Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis.

Authors:  Massimiliano Mazzone; Gabriele Bergers
Journal:  Annu Rev Physiol       Date:  2019-02-10       Impact factor: 19.318

3.  Hypoxia regulates the differentiation and anti-tumor effector functions of γδT cells in oral cancer.

Authors:  S K Sureshbabu; D Chaukar; S V Chiplunkar
Journal:  Clin Exp Immunol       Date:  2020-05-18       Impact factor: 4.330

4.  Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells.

Authors:  Ilkka Liikanen; Colette Lauhan; Sara Quon; Kyla Omilusik; Anthony T Phan; Laura Barceló Bartrolí; Amir Ferry; John Goulding; Joyce Chen; James P Scott-Browne; Jason T Yustein; Nicole E Scharping; Deborah A Witherden; Ananda W Goldrath
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 14.808

Review 5.  Lipids in the tumor microenvironment: From cancer progression to treatment.

Authors:  Kevin C Corn; McKenzie A Windham; Marjan Rafat
Journal:  Prog Lipid Res       Date:  2020-08-11       Impact factor: 16.195

Review 6.  Genetically Encoded Tools for Research of Cell Signaling and Metabolism under Brain Hypoxia.

Authors:  Alexander I Kostyuk; Aleksandra D Kokova; Oleg V Podgorny; Ilya V Kelmanson; Elena S Fetisova; Vsevolod V Belousov; Dmitry S Bilan
Journal:  Antioxidants (Basel)       Date:  2020-06-11

Review 7.  CD8+ T cell metabolism in infection and cancer.

Authors:  Miguel Reina-Campos; Nicole E Scharping; Ananda W Goldrath
Journal:  Nat Rev Immunol       Date:  2021-05-12       Impact factor: 53.106

Review 8.  Metabolic barriers to cancer immunotherapy.

Authors:  Kristin DePeaux; Greg M Delgoffe
Journal:  Nat Rev Immunol       Date:  2021-04-29       Impact factor: 53.106

Review 9.  Immunometabolic Interplay in the Tumor Microenvironment.

Authors:  Irem Kaymak; Kelsey S Williams; Jason R Cantor; Russell G Jones
Journal:  Cancer Cell       Date:  2020-10-29       Impact factor: 31.743

10.  Intratumoral Hypoxia Reduces IFN-γ-Mediated Immunity and MHC Class I Induction in a Preclinical Tumor Model.

Authors:  Aditi Murthy; Scott A Gerber; Cameron J Koch; Edith M Lord
Journal:  Immunohorizons       Date:  2019-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.